Intrivo's On/Go COVID-19 rapid self-test ranked No. 1 among seven leading tests by an independent patient safety group for ease of use, simplicity and quality of digital technology, as the On/Go mobile app tops Apple App Store medical chart – Yahoo Finance

– Intrivo's On/Go COVID-19 rapid self-test is named the most user-friendly among antigen home tests by ECRI, an independent healthcare quality and safety organization
– The companion On/Go mobile app was praised for its features and is ranked No. 1 in the Apple App Store amongst medical apps, with a 4.8-star rating
– On/Go is an FDA-authorized at-home COVID-19 antigen rapid test that delivers 95% accurate results in just 10 minutes and is widely available in stores and online, including for rapid home delivery
MIAMI, Jan. 11, 2022 /PRNewswire/ — Intrivo's On/Go COVID-19 rapid self-test was recognized as the top at-home COVID-19 test for its ease-of-use, clear instructions and supportive technology, compared to six other leading at-home COVID-19 tests, by ECRI, an independent healthcare quality and patient safety group. The independent non-profit conducted the first public comparison study of at home tests. ECRI assigned 12 staff engineers who ranked tests using a decades-old, industry-standard scale to rate designs of a broad range of products and services. They highlighted valuable On/Go app features like test timers and video guidance. The On/Go app also includes a secure passport for COVID-19 status, a service to help make gatherings and events safe, and a variety of resources to help manage positive test results for COVID-19. The On/Go mobile app is ranked No. 1 in the Apple App Store medical category, with a 4.8-star rating.
"We're deeply humbled by the recognition we are receiving for helping millions of people get tested and stay safer, healthier and happier," said Ron Gutman, co-CEO, Intrivo. "Our team is driven by empathy, which is why we listened to what people need and want, rigorously studied the science, and applied artisanship to build the optimal user experience that's crafted for quality, simplicity, speed and true care. Our team of top engineers, designers, and data specialists have put their whole heart into crafting a simple, powerful test plus tech solution to help everyone stay safe."
"For all of us at Intrivo, On/Go is personal and a labor of love, which is why people appreciate our solution so much," said Reeve Benaron, co-CEO, Intrivo. "Just last week, some of my immediate family tested positive with COVID-19 and the On/Go test and mobile app were a lifesaver. We were able to get our results in just ten minutes and isolate immediately to prevent infecting anybody else. The instructions in the app are easy enough for both my mother, who is in her 70s, and my young son who is 12 years old to follow, and remain healthy and safe."
To learn more about Intrivo's On/Go COVID-19 antigen rapid self-test and the On/Go mobile app, visit www.letsongo.com.
About Intrivo
Intrivo is a leading health-tech company harnessing the power of AI and user-centered design to help control COVID-19 while preparing the world to tackle the next health challenges and helping everyone live happier, healthier, safer lives.
Intrivo's market leading On/Go COVID solution combines testing plus technology to offer a trusted, comprehensive solution for consumers and enterprises alike to stay ahead of COVID-19. On/Go tests can be ordered directly at letsongo.com, or via our iOS and Android apps.
In the past year, Intrivo has served customers from Federal and State governments, to large employers, to healthcare systems, to the leading retailers, all the way to entertainment venues, cruise-lines, and families and individuals everywhere. Intrivo has delivered tens of millions of FDA-authorized COVID-19 tests worldwide, achieved multiple FDA and other authorizations across a variety of markets, while leveraging its superior patent-pending technology to help population health managers, and millions of users everywhere gain true peace of mind. While the company is currently focused on the global COVID-19 pandemic, it is actively expanding its solutions to make healthcare more accessible and affordable for both consumers and enterprises alike. To learn more about Intrivo and its world-class, tech-driven solutions, please visit www.intrivo.com.
The On/Go COVID-19 Antigen Self-Test has not been FDA cleared or approved but has been authorized by FDA under an Emergency Use Authorization (EUA). This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
Media Contact:
Laynie Held
lheld@intrivo.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/intrivos-ongo-covid-19-rapid-self-test-ranked-no-1-among-seven-leading-tests-by-an-independent-patient-safety-group-for-ease-of-use-simplicity-and-quality-of-digital-technology-as-the-ongo-mobile-app-tops-apple-app-store-med-301457895.html
SOURCE Intrivo
The pandemic accelerated a transformation Pfizer began years ago. Will Pfizer stock in 2022 continue to reflect the company's change?
Dozens of electric vehicle maker start-ups have appeared to capitalize on this coming sea change. Two small auto tech companies that investors should keep an eye on are Luminar Technologies (NASDAQ: LAZR) and Ambarella (NASDAQ: AMBA). In addition, tech giant Qualcomm (NASDAQ: QCOM) has been quietly building its presence in the automotive space, and looks like a great buy right now.
Microsoft's latest hire — taken directly from Apple — is seen as part of a push to build its own chips for its Azure servers amid a global processor shortage.
Analysts see risks in the cloud software sector, which may be heading for a shock from more moderate spending. Not so for Microsoft.
Pharmacokinetic simulation modeling study predicted more frequent administration with shorter dosing intervals (8 weeks vs. 10 weeks) would reduce serum testosterone fluctuations and elevate testosterone concentrations at the end of each maintenance dosing interval while maintaining acceptable levels of overall testosterone exposure
Allogene is pioneering off-the-shelf cell therapy using gene editing, so when the FDA placed a clinical hold on its clinical trials in the fall, it went to work to find answers for itself and the emerging field.
Companies like Intellia Therapeutics and Editas Medicine are saying that this year will bring exciting developments.
The White House will meet executives from leading tech firms, including Alphabet-owned Google, Apple Inc and Amazon.com Inc, on Thursday to discuss software security after the United States suffered several major cyberattacks last year. In December, White House National Security Advisor Jake Sullivan sent a letter to chief executives of tech firms after the discovery of a security vulnerability in open-source software called Log4j that organizations around the world use to log data in their applications. In the letter, Sullivan noted that such open source software is broadly used and maintained by volunteers and is a " key national security concern."
Following the spinout of its cancer business, bluebird bio Inc. is all in on gene therapy, with plans to launch three new drugs by the end of 2023.
T-Mobile holds an edge in 5G wireless spectrum but will its market share gains vs. AT&T and Verizon continue? Here is what fundamental and technical analysis says about buying TMUS stock.
Take-Two spent 12.7 billion on Zynga to grow its mobile division and fight Apple's privacy changes.
These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q1 2022.
(Bloomberg) — Microsoft Corp. lured away a veteran semiconductor designer from Apple Inc. as it looks to expand its own server-chips efforts, according to people with knowledge of the matter. Most Read from BloombergCannabis Compounds Prevented Covid Infection in Laboratory StudyFrequent Boosters Spur Warning on Immune ResponseSay Goodbye to Self-Isolating, WFH Mandates, Mass TestingEurope Slowly Starts to Consider Treating Covid Like the FluJ&J Vaccine Gets Additional Warning on Bleeding Side
A new study suggests that there may be some special health benefits hidden in cannabis plants that could help to block COVID-19
The outlook for CSCO stock depends on spending trends for cloud computing infrastructure as well as corporate and telecom networks amid the shift to remote work.
Unlike in previous years, when most Chinese tech funding went to internet startups in e-commerce, the bulk of the money in the past year headed into areas that hew more closely to Communist Party priorities, such as semiconductors, biotechnology and information technology.
Rising corporate spending on digital transformation projects has boosted CRM stock. With the Slack deal closed, merger synergies will be key.
If data are promising, Moderna says it will proceed with regulatory filings for the vaccine for children aged 2 to 5.
Tiny molecules in three acid compounds found in hemp prevent coronavirus from infecting human cells, an Oregon State University study found.
Many adults find themselves helping their aging parents with Medicare, a complex process with many steps and considerations. “You can’t go into it thinking it’s really easy,” says Melinda Caughill, co-founder of 65 Incorporated, which offers guidance on Medicare. “People should not make their first stop an insurance agent or an insurance company,” Caughill says.

source

Share:

More Posts

Market Research

Pulse Surveys

Turn feedback into action

Our survey platform makes it easy to measure and understand feedback so you can drive growth and innovation

Pulse Handshak

Pulse Handshak

Collaborative online survey tool for the market research industry. Remote assisted surveying just like face-to-face interviews. Here interviewers can talk to the respondent over the web-console without the need for any other communication channel and share the same Q're with responses and click actions.

Pulse FE

Pulse FE

Pulse Field Expert or Pulse FE is the main platform for both offline and online survey at softofficepro.com. It is robust and used by hundreds of clients over tens of years with millions of responses. Do it once Q're and deploy on both offline devices (android) and online forms makes it a great cost effective platform for any kind of responses

Pulse Ultimate

Pulse Ultimate

Pulse Ultimate is targeted for tracking studies and retail audits. An offline survey system offering extreme field control including processes like data quality check, back-check, rework, comparison with previous wave data etc. helps to get the best results on a day-to-day basis

Pulse LS

Pulse LS

Use a managed Limesurvey and our expertise for creating complex forms and token based user management. Use optional mailing system to send survey invitation to each participant and track progress of the response status. Industry standard SPSS / R output supported